Nestlé S.A. (NESN.SW)
| Previous close | 117.80 |
| Open | 117.92 |
| Bid | 0.00 x 0 |
| Ask | 118.82 x 0 |
| Day's range | 117.08 - 119.00 |
| 52-week range | 95.00 - 124.16 |
| Volume | |
| Avg. volume | 3,454,384 |
| Market cap | 334.652B |
| Beta (5Y monthly) | 0.22 |
| PE ratio (TTM) | 27.70 |
| EPS (TTM) | 4.29 |
| Earnings date | 17 Feb 2022 |
| Forward dividend & yield | 2.75 (2.33%) |
| Ex-dividend date | 19 Apr 2021 |
| 1y target est | N/A |
- Reuters
Nestle aims to nearly double sales via e-commerce by 2025
Nestle will push sales of its products to consumers directly via its own online channels, or direct to consumer, Nestle CEO Mark Schneider said, building on the success of Nespresso coffee pods and Purina PetCare, which are increasingly being sold directly to consumers via Nespresso.com and Purina.co.uk. "We plan to take (e-commerce) sales from about 13% in 2020 to 25% by 2025," Bernard Meunier, head of Nestle's strategic business units and marketing and sales, said at a virtual investor summit. This will be achieved by increasing digital marketing investment to 70% by 2025 from 47% in 2020, Meunier added.
- Yahoo Finance Video
Butterball CEO: 'We don’t expect a shortage of turkeys' for Thanksgiving
Jay Jandrain, Butterball CEO, tells Yahoo Finance that consumers can expect bigger birds and that turkeys will still be in supply for Thanksgiving despite inflation and supply chain challenges.
- Motley Fool
Why Shares of Seres Therapeutics Are Up More Than 22% Wednesday
The company's revenue was $126.7 million, compared with only $1.4 million year over year, with most of the increase from collaboration revenue from Seres' co-commercialization license agreement with Nestlé Health Science. The improved financial numbers were only part of the story. On Wednesday, Seres said it had established a collaboration with Swiss pharmaceutical company Bacthera to manufacture SER-109, Seres' lead therapy to treat recurrent Clostridioides difficle infection (rCDI).
